EA201070896A1 - ЗАМЕЩЕННЫЕ АРИЛАМИДДИАЗЕПИНОПИРИМИДОНОВЫЕ ПРОИЗВОДНЫЕ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ АНОМАЛЬНОЙ АКТИВНОСТЬЮ GSK3β - Google Patents
ЗАМЕЩЕННЫЕ АРИЛАМИДДИАЗЕПИНОПИРИМИДОНОВЫЕ ПРОИЗВОДНЫЕ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ АНОМАЛЬНОЙ АКТИВНОСТЬЮ GSK3βInfo
- Publication number
- EA201070896A1 EA201070896A1 EA201070896A EA201070896A EA201070896A1 EA 201070896 A1 EA201070896 A1 EA 201070896A1 EA 201070896 A EA201070896 A EA 201070896A EA 201070896 A EA201070896 A EA 201070896A EA 201070896 A1 EA201070896 A1 EA 201070896A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- group
- alkyl group
- atom
- optionally substituted
- substituted
- Prior art date
Links
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 title abstract 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000008318 pyrimidones Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290074A EP2090578A1 (en) | 2008-01-29 | 2008-01-29 | Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta |
| PCT/IB2009/000324 WO2009095789A1 (en) | 2008-01-29 | 2009-01-27 | Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of gsk3-beta |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201070896A1 true EA201070896A1 (ru) | 2011-02-28 |
Family
ID=39638986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201070896A EA201070896A1 (ru) | 2008-01-29 | 2009-01-27 | ЗАМЕЩЕННЫЕ АРИЛАМИДДИАЗЕПИНОПИРИМИДОНОВЫЕ ПРОИЗВОДНЫЕ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ АНОМАЛЬНОЙ АКТИВНОСТЬЮ GSK3β |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8507476B2 (enExample) |
| EP (2) | EP2090578A1 (enExample) |
| JP (1) | JP5611836B2 (enExample) |
| KR (1) | KR20100116592A (enExample) |
| CN (1) | CN101981032A (enExample) |
| AR (1) | AR070274A1 (enExample) |
| AU (1) | AU2009208728A1 (enExample) |
| BR (1) | BRPI0906618A2 (enExample) |
| CA (1) | CA2713256A1 (enExample) |
| EA (1) | EA201070896A1 (enExample) |
| IL (1) | IL207193A0 (enExample) |
| MX (1) | MX2010008363A (enExample) |
| NZ (1) | NZ587069A (enExample) |
| TW (1) | TW200936589A (enExample) |
| WO (1) | WO2009095789A1 (enExample) |
| ZA (1) | ZA201005384B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2090579A1 (en) * | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Substituted heteroarylamide diazepinopyrimidone derivatives |
| EP2085399A1 (en) * | 2008-01-29 | 2009-08-05 | Sanofi-Aventis | substituted arylamide oxazepinopyrimidone derivatives |
| EP2085400A1 (en) * | 2008-01-29 | 2009-08-05 | Sanofi-Aventis | Substituted heteroarylamide oxazepinopyrimidone derivatives |
| EP2138494A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EA201891620A1 (ru) * | 2016-02-05 | 2019-02-28 | Денали Терапьютикс Инк. | Ингибиторы взаимодействующей с рецептором протеинкиназы 1 |
| PL3552017T3 (pl) | 2016-12-09 | 2022-08-08 | Denali Therapeutics Inc. | Związki użyteczne jako inhibitory RIPK1 |
| CN107987090A (zh) * | 2017-12-19 | 2018-05-04 | 杨文思 | 一种用于治疗疟疾的恶性疟原虫糖原合成酶激酶-3抑制剂的合成方法 |
| US11382889B2 (en) * | 2018-04-19 | 2022-07-12 | Institut D'investigació Biomèdica De Bellvitge (Idibell) | NRF2 activators for the prevention and/or treatment of axonal degeneration |
| CN112516337B (zh) * | 2020-12-11 | 2022-08-12 | 南京邮电大学 | 近红外二区有机共轭聚合物荧光探针的制备方法及其应用 |
| MX2024008648A (es) | 2022-01-12 | 2024-09-23 | Denali Therapeutics Inc | Formas cristalinas de (s)-5-bencil-n-(5-metil-4-oxo-2,3,4,5-tetrah idropirido [3,2- b][1,4]oxacepin-3-il)-4h-1,2,4-triazol-3-carboxam ida. |
| CN116102488B (zh) * | 2023-01-05 | 2025-06-17 | 宁夏医科大学 | 3位具有不同氨基的2,3-二氨基丙酸衍生物的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EG13192A (en) | 1976-02-10 | 1982-12-31 | Rhone Poulenc Ind | Nouveaux derives du dithiole-1,2 leur preparation et les compositions qui les contiennent |
| US5629322A (en) | 1994-11-15 | 1997-05-13 | Merck & Co., Inc. | Cyclic amidine analogs as inhibitors of nitric oxide synthase |
| JP3188715B2 (ja) | 1995-11-01 | 2001-07-16 | メルク エンド カンパニー インコーポレーテッド | 一酸化窒素シンターゼの阻害物質としてのヘキサヒドロ−５−イミノ−１，４−ヘテロアゼピン誘導体 |
| US20030096813A1 (en) * | 2001-04-20 | 2003-05-22 | Jingrong Cao | Compositions useful as inhibitors of GSK-3 |
| CN1247586C (zh) * | 2001-09-21 | 2006-03-29 | 赛诺菲安万特 | 治疗神经退化性疾病的取代的2－嘧啶基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮及7－嘧啶基－2,3－二氢咪唑并[1,2－a]嘧啶－5(1h)酮衍生物 |
| EP1557417B1 (en) | 2003-12-19 | 2007-03-07 | Sanofi-Aventis | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives |
| EP1790649A1 (en) * | 2005-11-21 | 2007-05-30 | Sanofi-Aventis | Substituted bicyclic pyrimidone derivatives |
| EP2090579A1 (en) * | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Substituted heteroarylamide diazepinopyrimidone derivatives |
| EP2085399A1 (en) * | 2008-01-29 | 2009-08-05 | Sanofi-Aventis | substituted arylamide oxazepinopyrimidone derivatives |
| EP2085400A1 (en) * | 2008-01-29 | 2009-08-05 | Sanofi-Aventis | Substituted heteroarylamide oxazepinopyrimidone derivatives |
-
2008
- 2008-01-29 EP EP08290074A patent/EP2090578A1/en not_active Withdrawn
-
2009
- 2009-01-23 TW TW098103053A patent/TW200936589A/zh unknown
- 2009-01-27 CN CN2009801107249A patent/CN101981032A/zh active Pending
- 2009-01-27 CA CA2713256A patent/CA2713256A1/en not_active Abandoned
- 2009-01-27 KR KR1020107016906A patent/KR20100116592A/ko not_active Withdrawn
- 2009-01-27 EA EA201070896A patent/EA201070896A1/ru unknown
- 2009-01-27 MX MX2010008363A patent/MX2010008363A/es not_active Application Discontinuation
- 2009-01-27 NZ NZ587069A patent/NZ587069A/en not_active IP Right Cessation
- 2009-01-27 EP EP09706634.4A patent/EP2238141B1/en active Active
- 2009-01-27 AU AU2009208728A patent/AU2009208728A1/en not_active Abandoned
- 2009-01-27 JP JP2010544814A patent/JP5611836B2/ja not_active Expired - Fee Related
- 2009-01-27 BR BRPI0906618-7A patent/BRPI0906618A2/pt not_active IP Right Cessation
- 2009-01-27 WO PCT/IB2009/000324 patent/WO2009095789A1/en not_active Ceased
- 2009-01-28 AR ARP090100257A patent/AR070274A1/es unknown
-
2010
- 2010-07-25 IL IL207193A patent/IL207193A0/en unknown
- 2010-07-27 US US12/844,278 patent/US8507476B2/en not_active Expired - Fee Related
- 2010-07-28 ZA ZA2010/05384A patent/ZA201005384B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110039835A1 (en) | 2011-02-17 |
| NZ587069A (en) | 2011-12-22 |
| BRPI0906618A2 (pt) | 2015-07-14 |
| EP2090578A1 (en) | 2009-08-19 |
| US8507476B2 (en) | 2013-08-13 |
| TW200936589A (en) | 2009-09-01 |
| MX2010008363A (es) | 2010-08-30 |
| EP2238141A1 (en) | 2010-10-13 |
| WO2009095789A1 (en) | 2009-08-06 |
| JP5611836B2 (ja) | 2014-10-22 |
| IL207193A0 (en) | 2010-12-30 |
| KR20100116592A (ko) | 2010-11-01 |
| ZA201005384B (en) | 2011-10-26 |
| AU2009208728A1 (en) | 2009-08-06 |
| CA2713256A1 (en) | 2009-08-06 |
| AR070274A1 (es) | 2010-03-25 |
| EP2238141B1 (en) | 2015-01-14 |
| CN101981032A (zh) | 2011-02-23 |
| JP2011510970A (ja) | 2011-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201070896A1 (ru) | ЗАМЕЩЕННЫЕ АРИЛАМИДДИАЗЕПИНОПИРИМИДОНОВЫЕ ПРОИЗВОДНЫЕ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ АНОМАЛЬНОЙ АКТИВНОСТЬЮ GSK3β | |
| EA201070890A1 (ru) | Замещенные ариламидные производные оксазепинопиримидона | |
| CY1109890T1 (el) | ΠΑΡΑΓΩΓΑ 8-ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ-6,7,8,9- ΤΕΤΡΑΫΔΡΟΠΥΡΙΜΙΔΟ[1,2-α] ΠΥΡΙΜΙΔΙΝ-4-ΟΝΗΣ | |
| EA200970598A1 (ru) | Замещенные производные гетероарилпиридопиримидона | |
| PH12012502572A1 (en) | Novel nicotinamide derivative or salt thereof | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| MX2008012404A (es) | Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g. | |
| CY1111057T1 (el) | ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ ΤΗΣ 8-ΠΥΡΙΔΙΝΥΛΟ-ΔΙΥΔΡΟΣΠΕΙΡΟ-ΚΥΚΛΟΑΛΚΥΛΟ-ΠΥΡΙΜΙΔΟ 1,2-a ΠΥΡΙΜΙΔΙΝ-6-ΟΝΗΣ ΚΑΙ ΤΗΣ 8-ΠΥΡΙΜΙΔΙΝΥΛΟ-ΔΙΥΔΡΟΣΠΕΙΡΟ-ΚΥΚΛΟΑΛΚΥΛΟ-ΠΥΡΙΜΙΔΟ 1,2-a ΠΥΡΙΜΙΔΙΝ-6- ΟΝΗΣ ΚΑΙ Η ΧΡΗΣΗ ΑΥΤΩΝ ΕΝΑΝΤΙ ΤΩΝ ΝΕΥΡΟΕΚΦΥΛΙΣΤΙΚΩΝ ΝΟΣΩΝ | |
| NO20074668L (no) | Pyridal-eddiksyreforbindelser | |
| EA201170094A1 (ru) | Производные замещенного пиримидо[2,1-а]изохинолин-4-она | |
| EA201070891A1 (ru) | Замещенные гетероариламидные производные диазепинопиримидона | |
| ATE469144T1 (de) | Substituierte pyridonverbindungen und anwendungsverfahren | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| EA200501311A1 (ru) | ПРОИЗВОДНЫЕ ЗАМЕЩЁННОГО 8-ПЕРФТОРАЛКИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА | |
| EA201170095A1 (ru) | Производные (4-пиридин-4-ил)-1h-(1,3,5) триазин-2-она в качестве ингибирования gsk3-бета для лечения нейродегенеративных заболеваний | |
| ATE525351T1 (de) | Substituierte n-phenyl- bipyrrolidincarbonsäureamide und deren therapeutische verwendung | |
| EA201170099A1 (ru) | Замещенные пиримидин-4-оновые производные | |
| EA201070889A1 (ru) | Замещённые гетероариламидные производные оксазепинопиримидона | |
| ATE534625T1 (de) | Substituierte n-phenyl-bipyrrolidinharnstoffe und deren therapeutische verwendung | |
| ATE525350T1 (de) | Substituierte n-phenyl- bipyrrolidincarbonsäureamide und deren therapeutische verwendung | |
| EA200970455A1 (ru) | ЗАМЕЩЕННЫЙ 8-ПИПЕРИДИНИЛ-2-ПИРИДИНИЛПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОН И ПРОИЗВОДНЫЕ 8-ПИПЕРИДИНИЛ-2-ПИРИМИДИНИЛПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОНА | |
| EA200801134A1 (ru) | Замещенные бициклические пиримидоновые производные | |
| EA200971063A1 (ru) | Ариламидпиримидоновые соединения | |
| MX2009012383A (es) | Derivados de arilamida pirimidona para el tratamiento de enfermedades neurodegenerativas. | |
| EA201490754A1 (ru) | Производные карбамата/мочевины, содержащие пиперидиновые и пиперазиновые кольца, в качестве ингибиторов н3 рецептора |